canagliflozin vs ertugliflozin
Side-by-side comparison of canagliflozin and ertugliflozin Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Invokana
Steglatro
Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes. It can also help reduce the risk of heart problems and kidney disease in some patients.
Steglatro is a drug that combines ertugliflozin and metformin. It helps lower blood sugar in adults with type 2 diabetes, along with diet and exercise.
Invokana is used to help control blood sugar levels in adults with type 2 diabetes. It is used along with diet and exercise. Invokana can also lower the risk of major heart problems like heart attack and stroke in adults with both type 2 diabetes and heart disease. It can also reduce the risk of kidney failure, heart-related death, and hospitalization for heart failure in adults with type 2 diabetes and kidney problems.
Steglatro is used to help control blood sugar levels in adults with type 2 diabetes. You should use it along with a healthy diet and regular exercise. It is not for people with type 1 diabetes.
Invokana is a type of medicine called an SGLT2 inhibitor. It works by preventing your kidneys from reabsorbing sugar back into your blood. This causes extra sugar to leave your body through your urine, which lowers your blood sugar levels.
Steglatro contains two medicines. Ertugliflozin helps your kidneys remove sugar from your blood through urine. Metformin helps your body use insulin better and reduces sugar production in the liver.
- • Yeast infections of the vagina
- • Urinary tract infection
- • Increased urination
- • Diarrhea
- • Nausea
- • Vomiting
- • Gas
- • Stomach discomfort
- Diabetic ketoacidosis (high levels of ketones in the blood) 3,421
- Toe amputation 2,195
- Bone infection 2,163
- Sudden kidney damage 1,990
- Fungal infection 1,446
- Feeling sick to your stomach 86
- Problem with missing a dose 67
- Urinary tract infection 62
- Throwing up 59
- Fungal infection 58
Invokana can cause serious side effects, including: - Diabetic ketoacidosis (DKA): This is a serious condition where your body produces high levels of blood acids called ketones. DKA can be life-threatening. - Lower limb amputation: Invokana may increase your risk of needing an amputation of your foot or leg. - Volume depletion: Invokana can cause dehydration, which can lead to kidney problems and low blood pressure. - Serious infections: Invokana can increase your risk of urinary tract infections and a rare but serious infection of the tissue under the skin in the area between and around the anus and genitals (Fournier's gangrene).
Steglatro contains metformin, which can cause a serious side effect called lactic acidosis. This is a buildup of lactic acid in your blood. It can be life-threatening. Get medical help right away if you have symptoms like weakness, muscle pain, trouble breathing, stomach pain, or feel very sleepy.
Invokana is not recommended during the second and third trimesters of pregnancy because it may harm the developing baby's kidneys. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not recommended to use Invokana while breastfeeding.
Steglatro may harm your unborn baby, especially during the second and third trimesters. Breastfeeding is not recommended while taking Steglatro. Talk to your doctor if you are pregnant or plan to become pregnant.
Also Compare — Nearby Drugs
Compare canagliflozin with
Compare ertugliflozin with
How to Read This canagliflozin vs ertugliflozin Comparison
canagliflozin is classified in the SGLT2 Inhibitor drug class, while ertugliflozin sits within the SGLT2 Inhibitor class. Because both drugs share the same classification, they are often considered interchangeable in theory — but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, canagliflozin has 11,215 submissions while ertugliflozin has 332. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between canagliflozin and ertugliflozin — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.